Physician profile
Marcus C Roberts
NPI 1699731026
$939.01
in general payments reported to CMS, 2019-2025
21 companies · $53.68 in 2025
The $53.68 reported for 2025 was less than what a typical Hospice and Palliative Medicine (Family Medicine) provider received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $64.15 · 2021: $236 · 2022: $35.78 · 2023: $89.72 · 2024: $122 · 2025: $53.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248.55 | 2019-2022 | |
| Astellas Pharma US INC | $99.32 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $63.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.43 | 2019-2020 | |
| Lilly USA, LLC | $60.86 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $41.62 | 2019-2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $38.97 | 2019 | |
| Valeritas, INC. | $33.49 | 2019 | |
| Amarin Pharma, INC. | $32.98 | 2019-2020 | |
| Abbvie INC. | $32.88 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $25.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $24.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.88 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.76 | 2024 | Caplyta |
| Dexcom, INC. | $22.07 | 2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.35 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $19.54 | 2025 | Fanapt |
| Pfizer INC. | $19.26 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.49 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.77 | 2019 | |
| Ibsa Pharma INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.